The content on this site is intended for healthcare professionals only
Prof Arnold Vulto speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the sustainability of the biosimilar market.
He explains the factors that affect this market and that multi-winner tenders present the best outcome for the sustainability of the market.
Prof Vulto acknowledges that although biosimilars present the same efficacy and safety, there are differences - such as support, stability and combination partners.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.
Prostate cancer
Breast cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 4th - 10th, 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
